Nosocomial and Community Acquired Legionella Pneumophila Pneumonia.

Nosocomial and Community Acquired Legionella Pneumophila Pneumonia, a Retrospective Case Series

Sponsors

Lead Sponsor: Dr Philippe CLEVENBERGH

Source Brugmann University Hospital
Brief Summary

Legionnaire's disease (LD) is a major cause of both community acquired and nosocomial pneumonia, with Legionella pneumophila serogroup A (Lp1) being the most virulent and the greatest cause of disease. Sample culture of low respiratory tract is considered the gold standard in the diagnosis of LD, however its sensitivity seems to be poor and its performance is technically demanding. The introduction of urinary antigen detection testing (LUA) brought a major advance in LD diagnosis, with upt to 95% of cases in Europe being diagnosed with this method. Despite the high sensitivity of LUA for Lp1, ranging from 80-90%, its negative predictive value is low in other serogroup than Lp1 and therefore, Legionella may be unrecognized as agent of pneumonia. Although underdiagnosed and underreported, LD represents the second most common cause of pneumonia requiring admission in intensive care unit (ICU). Average fatality rate of LD in Europe reaches 10%, but its mortality is considered to be even higher in nosocomial patients. Despite the higher fatality rate in hospitalized LD patients, poor is the knowledge on the risk factors that could induce disease and that increase mortality in the hospitalized population affected by LD. In order to shed more light on this topic a cohort of patients diagnosed with LD in the last 3 years will be retrospectively examined.

Overall Status Recruiting
Start Date 2019-08-13
Completion Date 2020-12-25
Primary Completion Date 2020-12-25
Study Type Observational
Primary Outcome
Measure Time Frame
All cause mortality 3 years
Severity respiratory failure 3 years
Secondary Outcome
Measure Time Frame
Age One day
Sex One day
Charlson comorbidity index One day
Smoking status One day
Nosocomial disease (yes/no) One day
C reactive protein One day
White blood cells One day
Creatinine One day
Urea One day
Chest X Ray One day
Method of diagnosis One day
Intensive care unit hospitalization One day
Antibiotics One day
Antibiotic treatment duration up to 40 days
Enrollment 46
Condition
Intervention

Intervention Type: Other

Intervention Name: Data extraction from medical files

Description: Data extraction from medical files

Arm Group Label: Legionnaires' disease

Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion Criteria: All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years, from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre and the UZ Brussel Hospitals. Exclusion Criteria: Pregnant women.

Gender:

All

Minimum Age:

18 Years

Maximum Age:

N/A

Healthy Volunteers:

No

Overall Official
Last Name Role Affiliation
Marco Moretti, MD Principal Investigator CHU Brugmann
Overall Contact

Last Name: Marco Moretti, MD

Phone: 3224773508

Email: [email protected]

Location
Facility: Status: Contact: Investigator:
CHU St Pierre Hospital | Brussels, 1650, Belgium Recruiting Nicolas Dauby, MD [email protected] Nicolas Dauby, MD Principal Investigator
Universitair Zienkenhuis Brussel | Brussels, Belgium Recruiting Sabine Allard, MD [email protected] Sabine Allard, MD Principal Investigator
CHU Brugmann | Brussel, 1020, Belgium Completed
Location Countries

Belgium

Verification Date

2019-12-01

Responsible Party

Type: Sponsor-Investigator

Investigator Affiliation: Brugmann University Hospital

Investigator Full Name: Dr Philippe CLEVENBERGH

Investigator Title: Head of Infectious Diseases Department

Has Expanded Access No
Condition Browse
Arm Group

Label: Legionnaires' disease

Description: All confirmed human cases of Legionnaires' disease diagnosed within the CHU Brugmann hospital within the last 3 years: from 01/01/2016 till 31/12/2018. A similar approach will be followed for the St Pierre Hospital and the UZ Brussel Hospital.

Patient Data No
Study Design Info

Observational Model: Cohort

Time Perspective: Retrospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News